Last update 08 Apr 2025

212Pb-AR-RMX

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals
Synonyms
212-Pb-Targeted-Alpha-Emmitter-Therapy, 212Pb-DOTAMTATE, 212Pb-DOTAMTATE (RadioMedix/Orano Med)
+ [13]
Target
Action
modulators
Mechanism
SSTR modulators(Somatostatin receptor modulators), Ionising radiation emitters
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neuroendocrine TumorsPhase 3
United States
01 Dec 2021
Somatostatin Receptor-Positive Neuroendocrine TumorPhase 2
United States
21 Dec 2021
Somatostatin Receptor-Positive Neuroendocrine TumorPhase 2
United States
21 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
yzbfazwnfo(filajggrie) = bplxjbuzrb jkmxvjhibd (oauxsiyvov, 32.0 - 63.0)
Positive
24 May 2024
177Lu-DOTATATE
yzbfazwnfo(filajggrie) = oszvzdwqgs jkmxvjhibd (oauxsiyvov, 10 - 25)
Not Applicable
Neuroendocrine Tumors
SSTR expressing
11
212Pb-DOTAMTATE at 67.6 µCi/kg/cycle
rkhxmzrwzw(xhvwqrkfbw) = vjjhbzvnfn ombfqhfjlz (atdueleume )
Positive
08 Aug 2022
Phase 1
10
qhdoqallxi(yjxunwhhwa) = oocugkmagm srmzzhtjwv (dlnxscixbt )
Positive
02 Jun 2022
Phase 1
Neuroendocrine Tumors
First line
SSTR Expression
20
uyhbtiqexw(cfmaqpjyrg) = jshjerqval yfkfruessa (gkuykxxphv )
Positive
20 May 2021
Not Applicable
16
vslzyjeina(npzuuzcesv) = 7/16 (43%) ujjmentoog (qehxyglufs )
Positive
18 Sep 2020
AlphaMedix 40.0 µCi/kg
Not Applicable
13
axiosvoniu(phtmgmiedu) = No clinically significant investigational drug-related hematological and renal toxicity was noted. kqtstfvmsa (qrkflnxrpx )
Positive
15 Aug 2020
Not Applicable
170
iooyjhajvu(taixnyblxy) = 12% rjmbkcyusa (hyuykszoyz )
-
29 Sep 2019
Not Applicable
-
nfobhiqnep(inpwncrhuk) = jlflioebkp gbmaxabewp (catrstpppy )
Positive
20 May 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free